PMP22 ROLE IN ASSESSING THE DEGREE OF DEMYELINATION IN DIABETIC POLYNEUROPATHY
Keywords:
polyneuropathy, type 2 diabetes mellitus, peripheral myelin protein 22.Abstract
This research is about study of the effect of immune factor sin the progress ion and severity of diabetic polyneuropathy (DPN) clinical manifestations, and of the myelin destruction degree of peripheral nerve sin patients with type 2 diabetes mellitus (DM). The study involved 62 patients with type 2 DM with symptomatic stages of DPN according to the classification of P.J. Dyck and P.K. Tomas (1999). Based on the results of ENMG there were the following results. In case of IIA and III stages of DPN the signs of mixed motor nerve lesion with axonopathy predominance were noted. In patients with IIB stage, the extensive damage to myelin was observed parallel with the intensification of axonal lesions. The dependence of antibodies level to peripheral myelin protein 22 (MP22), which is a marker of nerves demyelination degree, from the state of a cell and hum oral immunity was revealed. It was concluded that immune dysfunction could be considered one of the pathogenetic link of polyneuropathy due to autoimmune processes. In addition, as evidence there is the high level of PMP22 antibodies in patients with type 2 diabetes mellitus.
References
2. Гриб В.А. Електрофізіологічні особливості перебігу поліневропатії у хворих на цукровий діабет типу 2 / В.А. Гриб // Український медичний альманах. – 2010. – Т.13, №4 (додаток). – С. 28-31.
3. Данилова Л.И. Сахарный диабет и его осложнения: клинические варианты диабетической нейропатии: Методическое пособие / Под ред. Л.И. Даниловой, Н.Я. Ярошевич. – Минск, 2009.
4. Салтыков Б.Б. Взаимосвязь механизмов развития ангиопатии и нейропатии у больных сахарным диабетом 2-го типа / Б.Б. Салтыков, О.Е. Зиновьева // Архивпатологии. – 2012. – №3. – С. 26-29.
5. Andreassen C.S. Muscleweakness – aprogressive late complication in diabeticdistalsymmetric рolyneuropathy / C.S. Andreassen // Diabetes. – 2005. – Vol.55. – P. 806-812.
6. Brooks-Worrell B. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation / B. Brooks-Worrell, J.P. Palmer // ClinExpImmunol. – 2012. – Vol.167. – P. 40-46.
7. Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies / M.F. Ritz, J. Lechner-Scott, R.J. Scott [et al.] // J Neuroimmunol. – 2000. – Vol.104(2). – P. 155-163.
8. Characterization of a monoclonal antibody specific for human peripheral myelin protein 22 and its use in immunohistochemical studies of the fetal and adult nervous system / N.A. Gregson, G. Zhang, J. Pritchard [et.al.] // J Peripher Nerv Syst. – 2007. – Vol.12(1). – P. 2-10.
9. Developmental abnormalities in the nerves of peripheral myelin protein 22-deficient mice / S.A. Amici, W.A. Dunn, L. Notterpec // J. Neurosci Res. – 2007. – Vol.85(2). – P. 238-249.
10. Elevated Protein Carbonylation, and Misfolding in Sciatic Nerve from db/db and Sod1 (-/-) Mice: Plausible Link between Oxidative Stress and Demyelination / R.T. Hamilton, A. Bhattacharya, M.E. Walsh [et al.] // Muscle & Nerve. – 2011. – Vol.44 (6). – P. 947-956.
11. Entrapment in antimyelin-associated glycoprotein neuropathy / G.F. Catharina, C.N. Nicolette, H.J.W. John, F. Hessel //Journal of Neu-rology. – 2009. – Vol.256 (4). – Р. 620-624.
12. Muller D. Лечение невропатических болевых синдромов. Результаты открытого исследования препарата на основе пиримидиновых нуклеотидов / D. Muller // Международный неврологический журн. – 2011. – № 1 (39). – С. 48-50.
13. Peripheral myelin protein 22 is a constituent of inter cellular junction sin epithelia / L. Notterpek, K.J. Roux, S.A. Amici [et.al.] // PNAS. – 2001. – Vol.98 (№25). – Р. 14404-14409.
14. Peripheral myelin protein 22 is expressed in human central nervous system / Y. Ohsawa, T. Murakami, Miyazaki Y [et al.] // J. NeurolSci. – 2006. – Vol.15, 247(1). – P. 11-15.
15. Phillips B. Current state oftype 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? / B. Phillips, M. Trucco, N. Giannoukakis // Clin. Dev. Immunol. – 2011. – Vol.2011. – P. 432016.
16. Pittas A.G. Adipocytokines and insulin resistance / A.G. Pittas, N. Joseph, A.S. Greenberg // J Clin Endocrin Metabol. – 2004. – Vol.89. – Р. 447-452.
17. Storm A. Pronounced reduction of cutaneous Langerhans cell density in recently diagnosed type 2 diabetes / A. Storm, J. Bruggenmann, I. Ziegler // Diabetes. – 2014. – Vol.64(3). – Р. 1148-1153.
18. Rickey E. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy / E.С. Rickey, J. William // Muscle and Nerve. – 2011. – Vol.44. – P. 340-345.
19. Seissler J. Autoimmune diagnostics in diabetes mellitus / J. Seissler, W.A. Scherbaum // Clin. Chem. Lab. Med. – 2006. – Vol.44, №2. – P. 133-137. http://www.ncbi.nlm.nih.gov/pubmed/20795891
